F S&P 500
5,120.25 +38.00 (+0.75%) F Dow Jones
38,317.00 +29.00 (+0.08%) F Nasdaq
17,755.50 +188.00 (+1.07%) E-mini Russell 2000 Index Futur
1,988.30 -4.90 (-0.25%) Petróleo
83.86 +0.29 (+0.35%) Oro
2,342.30 -0.20 (-0.01%)
InspireMD, Inc. (NSPR)
Fuera de horario:
InspireMD, Inc.
4 Menorat Hamaor Street
Tel Aviv 6744832
Israel
972 3 6917691
https://www.inspiremd.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 65
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Marvin L. Slosman | President, CEO & Director | 843.83k | N/D | 1964 |
| Mr. Craig Shore | CFO, Chief Administrative Officer, Secretary & Treasurer | 613.49k | N/D | 1961 |
| Dr. Patrick A. Verta DVM, M.D., MS Stat | Executive Vice President of Clinical & Medical Affairs | N/D | N/D | 1958 |
| Mr. Pete Ligotti | Executive VP & GM of North America | N/D | N/D | N/D |
| Dr. Sol J. Barer Ph.D. | Special Advisor to the Board | 13.92k | N/D | 1947 |
Descripción
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Gestión corporativa
La calificación ISS Governance QuickScore de InspireMD, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
